secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001641172-25-014905
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact
--------------------------------------------------------------------------------

- Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.
- Shareholders elected all four director nominees (Yu, Bae, Keyoung, Sighvi).
- Ratified Weinberg & Company as independent auditor for FY2025.
- Approved issuance of >20% common stock at price below NYSE American minimum price.
- Advisory votes approved executive compensation and 1-year frequency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225014905/0001641172-25-014905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225014905/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer